ArticlePLoS neglected tropical diseases2025
Reversal of filarial serpin Wb123-urokinase plasminogen activator receptor mediated alternative macrophage activation by monoclonal antibody.
Article in PLoS neglected tropical diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Potent inflammatory responses from host-parasite interactions in lymphatic filariasis are driven by macrophage polarization, which critically determines parasite survival or clearance. Evidence suggests that filarial parasite promote alternative macrophage polarization, facilitating immune evasion and persistent infection. However, the precise molecular mechanisms underlying filaria-induced alternative macrophage activation remain to be fully elucidated. Recently, serine protease inhibitors (serpins) have been implicated in alternative immune activation. Building on this insight, we explored and identified putative filarial serpins to be highly expressed in the infective L3 larval stage using in-silico analysis approach. Among all, Wb123, a serpin of Wuchereria bancrofti, the most predominantly found filarial worm, was cloned and purified to establish its role in alternative activation. We observed elevated markers of alternative activation; namely CD163, arginase-1, IL-6 and pSTAT3 expression, following rWb123 treatment. Furthermore, our results also indicated that rWb123 interacts with urokinase plasminogen activator receptor (uPAR) to activate the alternative activation pathway. Interestingly, rWb123 treatment attenuated the classical macrophage activation induced by lipopolysaccharide (LPS) and interferon-gamma (IFN-γ) as evident from muted CD86, nitric oxide (NO) and reactive oxygen species (ROS) expression. Notably, use of monoclonal antibody (MAbG8) to rWb123 or blocking uPAR impedes the rWb123-induced alternative activation and rescues the proinflammatory response to LPS-IFN-γ. These data confirmed that, uPAR dependent alternative activation by Wb123 enables filarial parasites to evade a strong pro-inflammatory immune response. Thus, targeting filarial serpins or uPAR could be potential therapeutics to re-establish immune response and eliminate filarial parasite from host.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.